Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C12H19NO2.H2O4S |
| Molecular Weight | 516.648 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CCCCNCC(O)C1=CC=C(O)C=C1.CCCCNCC(O)C2=CC=C(O)C=C2
InChI
InChIKey=PARMADWNFXEEFC-UHFFFAOYSA-N
InChI=1S/2C12H19NO2.H2O4S/c2*1-2-3-8-13-9-12(15)10-4-6-11(14)7-5-10;1-5(2,3)4/h2*4-7,12-15H,2-3,8-9H2,1H3;(H2,1,2,3,4)
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C12H19NO2 |
| Molecular Weight | 209.2848 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Bamethan (butyl-sympatol or vasculat) is an adrenaline derivative developed by C. H. Boehringer Sohn. Bamethan shows a depressor action on peripheral blood vessels as a result of the peripheral vasodilating action caused by stimulation of adrenergic beta-receptor. Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VASCULAT Approved UseBamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tandem mass spectrometry with online high-flow reversed-phase extraction and normal-phase chromatography on silica columns with aqueous-organic mobile phase for quantitation of polar compounds in biological fluids. | 2005 |
|
| Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. | 2002-06-20 |
|
| The effect of bamethan on cardiovascular response. | 1966-01-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:18 GMT 2025
by
admin
on
Mon Mar 31 17:47:18 GMT 2025
|
| Record UNII |
W2L3E1W827
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90972621
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
m2217
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
5716-20-1
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1987462
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
100000084970
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
W2L3E1W827
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
21955
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
227-214-9
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
DBSALT002804
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
SUB00660MIG
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
C76117
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
102345
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
C084810
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |